GSK, under pressure to perform, pens $2.2B deal with Alector focused on neuro R&D, Alzheimer's

GlaxoSmithKline is penning an upfront and biobucks combo deal worth up to $2.2 billion with Fierce 15 winner Alector in neurodegenerative diseases.

The deal sees the London-based company sign up with the U.S. biotech to co-develop and sell two “next generation” drugs for major neurodegenerative diseases including Parkinson’s and Alzheimer’s.